Login to Your Account



Repligen's Secretin Fails Autism Phase III; Subgroup Has Promise

By Karen Pihl-Carey


Tuesday, January 6, 2004
The new year greeted Repligen Corp. with disappointing data from its Phase III trial of synthetic human secretin in autism. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription